MedTrace Logo

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q4

NCT00608816 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-12-11

No results posted yet for this study

Summary

Epinephrine is one of the important hormones in the defense of hypoglycemia. We will test the hypothesis that antecedent hypoglycemia will blunt the metabolic, neuroendocrine and cardiovascular effects of subsequent epinephrine infusion in Type 1 DM.

Conditions

Interventions

DRUG

epinephrine

Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2

DRUG

epinephrine

Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Stephen N. Davis, MD · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608816 on ClinicalTrials.gov